Publication: Medición del impacto de un programa de atención farmacéutica en pacientes obesos o con sobrepeso
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-06-13
Authors
Advisors (or tutors)
Fernández Alfonso, Soledad
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La obesidad es una de las enfermedades más prevalentes en la actualidad y su aumento está directamente relacionado con el incremento en la incidencia de múltiples comorbilidades. La detección temprana, la educación sanitaria y el seguimiento nutricional son clave para la reducción del riesgo cardiovascular (RCV) en estos pacientes. La estrategia terapéutica inicial que se aplica a estos pacientes consiste en hacer cambios en el estilo de vida (dieta y ejercicio) a los que se añade posteriormente un tratamiento farmacológico. El objetivo de este estudio es desarrollar desde la farmacia comunitaria un protocolo de seguimiento del paciente obeso y con sobrepeso (Protocolo FarmaFit) que:i) mejore la calidad de vida y reduzca al máximo las comorbilidades asociadas y el riesgo cardiovascularii) que genere en el paciente una adherencia al cambio de hábitos, perdurable en el tiempo.iii) establezca una colaboración entre agentes sanitarios de atención al paciente, que permita reducir el coste de los tratamientos y el número de ingresos hospitalarios.El estudio se ha realizado en una farmacia comunitaria de Madrid. Se incluyeron pacientes obesos (índice de masa corporal, IMC ≥ 30) con (grupo A, n = 30) o sin (grupo B, n = 14) comorbilidades...
Obesity is one of the most prevalent diseases at present and its increase is directly related to the increase in the incidence of multiple comorbidities. Early detection, health education and nutritional follow-up are key for cardiovascular risk (CVR) reduction in these patients. The initial therapeutic strategy applied to these patients consists of making changes in lifestyle (diet and exercise) to which a pharmacological treatment is added later. The objective of this study is to develop, from the community pharmacy, a monitoring protocol for obese and overweight patients (FarmaFit Protocol) that:i) improves the quality of life and minimize the associated comorbidities and cardiovascular riskii) that generates in the patient an adherence to the change of habits, lasting over time.iii) establishes a collaboration between health agents of patient care, which allows reducing the cost of treatments and the number of hospital admissions.The study was carried out in a community pharmacy in Madrid...
Obesity is one of the most prevalent diseases at present and its increase is directly related to the increase in the incidence of multiple comorbidities. Early detection, health education and nutritional follow-up are key for cardiovascular risk (CVR) reduction in these patients. The initial therapeutic strategy applied to these patients consists of making changes in lifestyle (diet and exercise) to which a pharmacological treatment is added later. The objective of this study is to develop, from the community pharmacy, a monitoring protocol for obese and overweight patients (FarmaFit Protocol) that:i) improves the quality of life and minimize the associated comorbidities and cardiovascular riskii) that generates in the patient an adherence to the change of habits, lasting over time.iii) establishes a collaboration between health agents of patient care, which allows reducing the cost of treatments and the number of hospital admissions.The study was carried out in a community pharmacy in Madrid...
Description
Tesis de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacología, Farmacognosia y Botánica, leída el 11-12-2018